New England Research & Management’s Charles River Laboratories CRL Stock Holding History

New England Research & Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,450	Closed	-$506K	–	163
2024 Q2	$506K	Buy	+2,450	New	+$555K	0.24%	121
2020 Q1	–	Sell	-4,500	Closed	-$687K	–	144
2019 Q4	$687K	Sell	4,500 -2,225	-33%	-$308K	0.46%	79
2019 Q3	$890K	Sell	6,725 -250	-4%	-$33.5K	0.64%	54
2019 Q2	$990K	Buy	+6,975	New	+$946K	0.67%	49
2019 Q1	–	Sell	-3,300	Closed	-$373K	–	170
2018 Q4	$373K	Sell	3,300 -7,500	-69%	-$939K	0.29%	103
2018 Q3	$1.45M	Buy	+10,800	New	+$1.33M	0.95%	34

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

New England Research & Management's CRL Position: Q3 2024 in Review

New England Research & Management sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 2,450 shares — an estimated $506K sold.

New England Research & Management first reported a position in CRL in Q3 2018 and held it in 6 quarters. The position peaked at $1.45M in Q3 2018. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

New England Research & Management reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
New England Research & Management sold 2,450 Charles River Laboratories shares in Q3 2024, an estimated $506K.
New England Research & Management first reported a position in Charles River Laboratories in Q3 2018 and held it in 6 quarters.
New England Research & Management's Charles River Laboratories position peaked at $1.45M in Q3 2018.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on New England Research & Management's 13F filing for Q3 2024, filed 7 Oct 2024.